Global BulletinAll NewsFDA Approval AlertWomen in Oncology
Expert InterviewsAround the PracticeBetween the LinesFace OffFrom All AnglesMeeting of the MindsOncViewPodcastsTraining AcademyTreatment Algorithms with the Oncology Brothers
Conferences
All JournalsEditorial BoardFor AuthorsYear in Review
Frontline ForumSatellite Sessions
CME/CE
Awareness MonthInteractive ToolsNurse Practitioners/Physician's AssistantsPartnersSponsoredSponsored Media
Career CenterSubscribe
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
Spotlight -
  • Radiation Oncology
  • Surgery
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
    • Conferences
    • CME/CE
    • Career Center
    • Subscribe
Advertisement

Possible Hereditary Link Between Ovarian and Testicular Cancers Observed

March 20, 2018
By Dave Levitan
Article

A registry study suggests that there may be a familial association between ovarian and testicular cancers.

A registry study suggests that there may be a familial association between ovarian and testicular cancers. In the study, men with testicular cancer were more likely to have a mother with ovarian cancer compared with men with other malignancies.

Testicular germ cell tumors (TGCT) are the most common malignancies among American men aged 15 to 44 years; family history of TGCT has been well established as a risk factor for these tumors. “Although familial TGCT studies have yet to characterize TGCT syndromic patterns, a biologically plausible link between TGCT and ovarian germ cell tumors has been posited,” wrote study authors led by Kirsten B. Moysich, PhD, of the Roswell Park Comprehensive Cancer Center in Buffalo.

The investigators conducted a study using data from the Familial Ovarian Cancer Registry to test for associations between ovarian cancer and TGCT. They included a total of 2,636 families with multiple cases of ovarian cancer. Results were published in Cancer Epidemiology.

The cohort contained 34 men with testicular cancer, and 2,894 men with non-testicular cancers. Of those 34 men, 24 had mothers with known ovarian cancer status, and 10 mothers (41.67%) had ovarian cancer while 14 did not. This meant that the men with testicular cancer were significantly more likely to have a mother with ovarian cancer compared with the men with other malignancies, with an odds ratio (OR) of 3.32 (95% CI, 1.46–7.55; P = .004). The same was true for having a sister with ovarian cancer, though this did not reach significance, with an OR of 1.66 (95% CI, 0.87–3.15; P = .124); of the 43 sisters of men with testicular cancer with known ovarian cancer status, 14 (32.56%) had ovarian cancer.

The men in the registry with testicular cancer fathered 13 daughters, but these daughters were either too young to be at risk for ovarian cancer, or lacked adequate follow-up. Four of 16 maternal grandmothers had ovarian cancer (25%), and none of 9 paternal grandmothers with known status had the malignancy.

The mechanism for this connection may involve X-chromosome–linked susceptibility genes, the authors wrote. “While the observed absence of ovarian cancer in paternal grandmothers of men with testicular cancer is consistent with X-linked transmission, analyses were limited by small sample sizes and X-linkage could not be conclusively established,” they noted.

An attempt to update the registry and improve the family histories and collection of biospecimens is underway, specifically in families with multiple cases of ovarian cancer as well as at least one case of testicular cancer. “These analyses may provide insight into the etiology of transmission patterns of both cancers and expose novel gene targets for prevention and therapy,” the authors wrote.

Recent Videos
Approximately 10% of patients discontinued treatment with avutometinib/defactinib due to toxicity in the phase 2 RAMP 201 trial.
Response rates appeared to be higher with avutometinib plus defactinib vs avutometinib alone in the phase 2 RAMP 201 study.
Patients who respond to avutometinib/defactinib may be maintained on treatment for long periods of time, says Rachel N. Grisham, MD.
Findings from the OVARIO study show that patients with HRR–deficient and BRCA-mutated disease benefitted the most from niraparib/bevacizumab maintenance.
Select comorbidities, ECOG status, and the receipt of radiation were among the differences between a real-world cohort and the RUBY trial population.
Next-generation clinical trials may address when to use CDK4/6 inhibition in patients with low-grade serous ovarian cancer.
The NRG-GY019 trial will assess chemotherapy plus letrozole vs letrozole alone as a frontline treatment for patients with low-grade serous ovarian cancer.
Nearly 40% of low-grade serous ovarian cancers have RAS alterations, which are predominately KRAS mutations.
Related Content
Advertisement

The safety profile of pembrolizumab in the KEYNOTE-B96 study was comparable with prior reports of the agent, and investigators observed no new safety signals.

Pembrolizumab Combo Extends PFS in Platinum-Resistant Ovarian Cancer

Russ Conroy
May 15th 2025
Article

Data from the KEYNOTE-B96 trial also show a significant overall survival improvement with pembrolizumab-based treatment in PD-L1–positive disease.


Low grade serous ovarian cancer, a rare epithelial ovarian cancer subtype, requires differentiated treatment from its high-grade counterpart.

Redefining the Treatment Paradigm in Low Grade Serous Ovarian Cancer

Kathleen N. Moore, MD, MS
March 17th 2025
Podcast

Low grade serous ovarian cancer, a rare epithelial ovarian cancer subtype, requires differentiated treatment from its high-grade counterpart.


The FDA originally approved this thiotepa formulation as a therapy for patients with breast or ovarian cancers in June 2024.

FDA Approves Multidose Thiotepa Vial for Breast and Ovarian Cancers

Russ Conroy
April 30th 2025
Article

The regulatory decision may offer more scheduling flexibility for patients who receive thiotepa for breast or ovarian cancer.


Uterine transposition, a surgical approach preserving fertility by moving the uterus out of the radiation field, may improve gynecologic cancer outcomes.

Uterine Transposition May Maintain Fertility Following Pelvic Radiotherapy

John Paul Diaz, MD
November 4th 2024
Podcast

Uterine transposition, a surgical approach preserving fertility by moving the uterus out of the radiation field, may improve gynecologic cancer outcomes.


Nemvaleukin/Pembrolizumab Yield No OS Improvement in Ovarian Cancer

Nemvaleukin/Pembrolizumab Yield No OS Improvement in Ovarian Cancer

Tim Cortese
March 26th 2025
Article

The phase 3 ARTISTRY-7 trial has been halted and nemvaleukin is no longer being developed for the treatment of patients with platinum-resistant ovarian cancer.


Future research may explore predictors of interval debulking surgery success and the scope of required surgery in advanced ovarian cancer.

Data Show Need for Specialized Expertise in Advanced Ovarian Cancer Surgery

Russ Conroy
March 19th 2025
Article

Future research may explore predictors of interval debulking surgery success and the scope of required surgery in advanced ovarian cancer.

Related Content
Advertisement

The safety profile of pembrolizumab in the KEYNOTE-B96 study was comparable with prior reports of the agent, and investigators observed no new safety signals.

Pembrolizumab Combo Extends PFS in Platinum-Resistant Ovarian Cancer

Russ Conroy
May 15th 2025
Article

Data from the KEYNOTE-B96 trial also show a significant overall survival improvement with pembrolizumab-based treatment in PD-L1–positive disease.


Low grade serous ovarian cancer, a rare epithelial ovarian cancer subtype, requires differentiated treatment from its high-grade counterpart.

Redefining the Treatment Paradigm in Low Grade Serous Ovarian Cancer

Kathleen N. Moore, MD, MS
March 17th 2025
Podcast

Low grade serous ovarian cancer, a rare epithelial ovarian cancer subtype, requires differentiated treatment from its high-grade counterpart.


The FDA originally approved this thiotepa formulation as a therapy for patients with breast or ovarian cancers in June 2024.

FDA Approves Multidose Thiotepa Vial for Breast and Ovarian Cancers

Russ Conroy
April 30th 2025
Article

The regulatory decision may offer more scheduling flexibility for patients who receive thiotepa for breast or ovarian cancer.


Uterine transposition, a surgical approach preserving fertility by moving the uterus out of the radiation field, may improve gynecologic cancer outcomes.

Uterine Transposition May Maintain Fertility Following Pelvic Radiotherapy

John Paul Diaz, MD
November 4th 2024
Podcast

Uterine transposition, a surgical approach preserving fertility by moving the uterus out of the radiation field, may improve gynecologic cancer outcomes.


Nemvaleukin/Pembrolizumab Yield No OS Improvement in Ovarian Cancer

Nemvaleukin/Pembrolizumab Yield No OS Improvement in Ovarian Cancer

Tim Cortese
March 26th 2025
Article

The phase 3 ARTISTRY-7 trial has been halted and nemvaleukin is no longer being developed for the treatment of patients with platinum-resistant ovarian cancer.


Future research may explore predictors of interval debulking surgery success and the scope of required surgery in advanced ovarian cancer.

Data Show Need for Specialized Expertise in Advanced Ovarian Cancer Surgery

Russ Conroy
March 19th 2025
Article

Future research may explore predictors of interval debulking surgery success and the scope of required surgery in advanced ovarian cancer.

Advertisement
About
Advertise
CureToday.com
OncLive.com
OncNursingNews.com
TargetedOnc.com
Editorial
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.